This startup is developing a non-invasive drug delivery system using an octopus-inspired suction patch applied to the inner cheek. This technology allows medicines to efficiently enter the bloodstream, offering a painless alternative to traditional drug administration methods.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients requiring injectable medications, such as those with type 2 diabetes or osteoporosis, face the burden of frequent and painful subcutaneous injections. Oral administration of peptide and protein drugs is often not feasible due to degradation in the digestive tract or poor absorption.
Solution
OBaris offers a painless alternative to injectable drugs with the OctoPatch®, a small, self-administered patch applied to the inner cheek. Inspired by octopus suckers, the patented technology uses negative pressure and permeation enhancers to temporarily disrupt the mucosal barrier, enabling efficient drug absorption into the bloodstream. The OctoPatch® eliminates the need for needles, offering a convenient and less invasive method for delivering medications that are typically administered via injection. The patch is designed for short-term application and easy removal.
Target Audience
The primary target audience includes patients who require frequent injections of medications, particularly those with chronic conditions like type 2 diabetes or osteoporosis, and pharmaceutical companies seeking innovative drug delivery methods.
Features
- Needle-free drug delivery via a self-administered buccal patch
- Octopus-inspired suction mechanism for enhanced adhesion and drug permeation
- Utilizes negative pressure to temporarily disrupt the buccal mucosa barrier
- Employs natural permeation enhancers to facilitate drug absorption
- Designed for rapid drug delivery and short application time
- Suitable for peptide and protein drugs that are not effectively absorbed orally